SVEC4-10（小鼠淋巴內(nèi)皮細胞（SV40轉化））
CBP60997
詢 價
索取STR
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
| I. General information | |
| Synonyms: | SVEC4-10 |
| Background: | SVEC4-10 is an endothelial cell line derived by SV40 (strain 4A) transformation of endothelial cells from axillary lymph node vessels. |
| Species: | Mus musculus, mouse |
| Tissue: | axillary lymph node/vascular epithelium |
| Gender: | male, adult |
| Morphology: | epithelial |
| Growth Mode: | adherent |
| Doubling Time: | 24 to 30 hrs |
| Culture Medium: |
DMEM+10%FBS SVEC4-10完全培養(yǎng)基，# CBP60997M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Antigen Expression: | H-2 K; Factor VIII related antigen; VCAM |
| Receptor Expression: | high affinity receptors for low density lipoprotein (LDL) |
| Tumor Formation: | Yes, the cells induce spindle tumors with some of the histopathologic characteristics of human Kaposi Sarcoma after a latency period of approximately 14 weeks |
| Comments: | They grow indefinitely without special additives and are well differentiated, responding like normal endothelial cells to some interleukins and to extracellular matrix signals for tube-like differentiation. When grown on a synthetic basement-like membrane, SVEC4-10 forms branching tube-like networks. They specifically bind mouse lymphocytes in vitro. The cells express the cell surface major histocompatibility complex class I antigen, H-2 k, and are susceptible to lysis by anti SV40 H-2 k CTL clones. Interferon gamma (IFN-gamma) induces expression of MHC class II antigen in a time course identical to that of normal endothelial cells. The cells express vascular cell adhesion molecule (VCAM), and stain positively for SV40 T antigen. Tumor necrosis factor alpha (TNF alpha) induces SVEC4-10 to undergo reversible transition to a spindle shaped morphology. SVEC4-10 is the parental line for a series of endothelial cell clones (ATCC CRL-2160, ATCC CRL-2161, ATCC CRL-2162, ATCC CRL-2163, ATCC CRL-2167, ATCC CRL-2168 and ATCC CRL-2171) For more information, please contact us (4008-750-250). |
